Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 16;13:1373. doi: 10.1038/s41467-022-29040-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — Endometrial cancer recurrence-free survival calculated according to Kaplan-Meier’s methodology and tested between patients with and without TLS using a two-sided log rank test (alpha 0.05). a Patients with POLEmut endometrial cancer (N = 47) and MMRd endometrial cancer (N = 127). b Patients with p53abn endometrial cancer (N = 83) and NSMP endometrial cancer (N = 121). TLS Tertiary lymphoid structure; POLEmut Pathogenic polymerase epsilon mutation; MMRd Mismatch repair deficient; p53abn p53 abnormal; NSMP No specific molecular profile.